압타바이오

293780KOSDAQ자연과학 및 공학 연구개발업

54.1 / 100

Reference Date: 2026-06-10

Financial Score19.5 / 40

News Sentiment20.6 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Plunged 36.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

AptaBio is a specialized pharmaceutical company developing innovative drugs based on three platform technologies: oxidative stress modulation, CAF Modulation, and aptamer-drug conjugate (Apta-DC). The company focuses on drug pipeline development, including eight therapeutic candidates, and expanded into health functional food ODM and pet care businesses through its newly established New Business Division in 2023. Key revenue streams include technology fees, reagent sales, and product sales from new business segments.

Number of Employees

45people

Average Salary

57.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

3.04Industry Average 3.244.0Point

In line with industry avg

ROE

-32.25Industry Average -32.093.5Point

In line with industry avg

Debt Ratio

6.63Industry Average 7.314.0Point

In line with industry avg

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲473.9% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲0.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -34.8% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 82.5

Positive
압타바이오, 면역항암제 'APX-343A' 키트루다 병용 임상 개시
압타바이오의 면역항암제 APX-343A와 키트루다 병용 임상 시작으로 임상 진입 기대감 상승.
Positive
압타바이오, 차세대 면역항암제 1상 데이터 긍정적…“6월 키트루다 ....
압타바이오의 차세대 면역항암제 APX-343A가 임상 1상에서 긍정적인 동물실험 결과를 보여주며 주가 상승 기대.
Positive
압타바이오, 바이오 USA 참가…글로벌 기술이전 협상 확대
압타바이오의 글로벌 기술이전 협상 확대 소식으로 인해 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 5,110Won52-week high 10,44052-week low 5,110

1-month return0.0Point

1m -36.12% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15